Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 3, 2008, Pages 237-243

  Amato, Robert J ^a   Malya, Rahul ^a   Rawat, Anish ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Granulocyte macrophagecolony stimulating factor; Interleukin 2; Renal cell carcinoma; Thalidomide

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BONE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; FEMALE; FLU LIKE SYNDROME; FLUID RETENTION; HUMAN; INDUCED HYPOTENSION; KIDNEY CARCINOMA; LEUKOCYTOSIS; LYMPHOCYTOSIS; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FATIGUE; HEMATOLOGIC DISEASE; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CONSTIPATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; SURVIVAL RATE; THALIDOMIDE;

EID: 44949146378     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31815e4505     Document Type: Article

References (62)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics. Cancer J Clin. 2006;56:106-130.
2. Weiss LM, Gelb AB, Medeiros LJ. Adult renal epithelial neoplasms. Am J Clin Pathol. 1995;103:624-625.
3. Kovacs G. Molecular differential pathology of renal cell tumours. Histopathology. 1993;22:1-8.
4. Ritchie AWS, Chisholm GD. The natural history of renal carcinoma. Semin Oncol. 1983;10:390-400.
5. Giuliani L, Giberti C, Martorana G, et al. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol. 1990;143:468-474.
6. Linehan WM, Zhar B, Bates SE. Cancer of the kidney and ureter. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:1362-1396.
7. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
8. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000; 27:177-186.
9. Amato RJ. Thalidomide: an antineoplastic agent. Curr Oncol Rep. 2002;4:56-62.
10. Zisman A, Pantuck AJ, Belldegrun AS. Molecular-based therapies for renal cell carcinoma. Curr Urol Rep. 2001;2:55-61.
11. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Huntingt). 2002; 16(suppl 13):4-10.
12. Fishman M, Seigne J. Immunotherapy of metastatic renal cell Cancer. Cancer Control. 2002;9:293-304.
13. Negrier S, Maral J, Drevon M, et al. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant inter-leukin-2 in Europe. Cancer J Sci Am. 2000;6(suppl 1):S93-S98.
14. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76:824-832.
15. Lee DS, White DE, Hurst R, et al. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J Sci Am. 1998;4:86-93.
16. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002;29(suppl 7):41-46.
17. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417.
18. Motzer RJ, Bahnson RR, Carducci MA, et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology - v. 1. Kidney Cancer. Jenkintown, PA: National Comprehensive Cancer Network; 2003.
19. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
20. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
21. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
22. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19:148-154.
23. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1):S55-S57.
24. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997;80:1198-1220.
25. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
26. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus inter- leukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133-3140.
27. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am. 1993;20:283-295.
28. Stadler WM, McKay S, Ryback E, et al. Subcutaneous granulocyte macrophage colony stimulating factor (GM-CSF) with or without oral pentoxifylline in the treatment of patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 1995;14:A6430.
29. Wos E, Olencki T, Tuason L, et al. Phase II trial of subcutaneously administered granulocyte-macrophage colony stimulating factor in patients with metastatic renal cell carcinoma. Cancer. 1996;77:1149-1153.
30. Steger GG, Kaboo R, deKernion JB, et al. The effects of granulocyte-macrophage colony-stimulating factor in tumor-infiltrating lymphocytes from renal cell carcinoma. Br J Cancer. 1995;72:101-107.
31. Schiller JH, Hank JA, Khorsand M, et al. Clinical immunological effects of granulocyte macrophage-colony stimulating factor co-administered with interleukin-2: a phase 1 B study. Clin Cancer Res. 1996;2:319-330.
32. Presti JC Jr, Rao PH, Chen Q, et al. Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res. 1991; 51:1544-1552.
33. Zambrano NR, Lubensky IA, Merino MJ, et al. Histopathology and molecular genetics of renal tumors: toward unification of a classification system. J Urol. 1999;162:1246-1258.
34. Blancher C, Moore JW, Robertson N, et al. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1, HIF-2, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res. 2001;61:7349-7355.
35. Maxwell PH, Wiesener MS, Chang G-W, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275.
36. Rasmuson T, Grankvist K, Jacobsen J, et al. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer. 2001;37:2199-2203.
37. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
38. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol. 2000;12:564-573.
39. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
40. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971-978.
41. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;31:213-221.
42. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology. 1995;31:109-116.
43. Haslett PAJ, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset. J Exp Med. 1998;187:1885-1892.
44. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodu- latory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
45. Amato R. Thalidomide for recurrent renal cell-cancer in a 40-year-old man. Oncology (Huntingt). 2000;14(suppl 13):33-36.
46. Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast Cancer. Br J Cancer. 2000;82:812-817.
47. Novik Y, Dutcher JP, Larkin M, et al. Phase II study of thalidomide (T) in advanced refractory metastatic renal cell carcinoma (MRCC): a single institution experience. Proc Am Soc Clin Oncol. 2001;20:265a(abstr 1057).
48. Li Z, Amato R, Papandreou C, et al. Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proc Am Soc Clin Oncol. 2001;20:180a(abstr 717).
49. Motzer RJ, Berg W, Ginsberg M, et al. Phase II trials of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002;20:302- 306.
50. Minor D, Elias L. Thalidomide treatment of metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2000;19:352a(abstr 1384).
51. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol. 2002;13:1029-1035.
52. Stebbing J, Benson C, Eisen T, et al. The treatment of advanced renal cell cancer with high-dose thalidomide. Br J Cancer. 2001;85:953-958.
53. Srinivas S, Guardino AE. Randomized trial of high and low dose thalidomide in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2002;21:147b(abstr 2403).
54. Morgan M, Rawat A, Amato RJ. Phase II study of thalidomide, inter-leukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients (pts) with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol. 2005;23:432s(abstr 4717).
55. Amato RJ, Morgan M, Rawat A. phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer. 2006;106:1498-1506.
56. Rabinoiwtz M, Elias L, Lee FC. Phase I/II trial of 5-fluorouricil, interferon-a, interleukin-2, and thalidomide for metastatic renal cell Cancer. Proc Am Soc Clin Oncol. 2003;22:445(abstr 1788).
57. Olencki T, Malhi S, Mekhail R, et al. Phase I trial of thalidomide and interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2003;22:387(abstr 1554).
58. Sella A, Sternberg C, Yarom N, et al. Phase II study of low dose thalidomide and interferon-alfa in metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2003;22:402(abstr 1614).
59. Ridenhour KP, Kubinski D, Stindt D, et al. Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma. Proc Am Soc Clin Oncol. 2002;21:154b(abstr 2429).
60. Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol. 2002;20:1429-1430.
61. Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240:1169-1176.
62. Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a phase II, placebo controlled, randomized discontinuation trial (RDT) of sorfenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2005;23:388(abstr 4544).